Aditx Therapeutics, Inc. (ADTX)
Stock Price: $2.37 USD
0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $2.35 -0.02 (-0.84%) Jan 15, 7:45 PM
| Market Cap | 28.98M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 7.44M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $2.37 |
| Previous Close | $2.37 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 2.46 |
| Day's Range | 2.31 - 2.47 |
| Day's Volume | 772,204 |
| 52-Week Range | 1.70 - 7.60 |
News
There are no news available yet.
About ADTX
ADiTx Therapeutics, a life sciences company, focuses on developing nucleic acid-based technologies for addressing the rejection of transplanted organs, autoimmune diseases, and allergies. The company is developing Apoptotic DNA Immunotherapy (ADi), a nucleic acid-based technology that utilizes an approach, which mimics the way the body naturally induces tolerance to its own tissues. It also develops ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. The company has a license agreement with Loma ... [Read more...]
| Industry Biotechnology | IPO Date Jun 30, 2020 |
| CEO Amro A. Albanna | Employees 2 |
| Stock Exchange NASDAQ | Ticker Symbol ADTX |